Biomerica, Inc. (BMRA) |
| 2.15 0.07 (3.37%) 04-14 15:46 |
| Open: | 2.0497 |
| High: | 2.15 |
| Low: | 2.0401 |
| Volume: | 23,908 |
| Market Cap: | 6(M) |
| PE Ratio: | -0.86 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Medical - Devices |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 2.23 |
| Resistance 1: | 2.12 |
| Pivot price: | 2.13 |
| Support 1: | 1.95 |
| Support 2: | 1.62 |
| 52w High: | 4.88 |
| 52w Low: | 1.87 |
Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, an irritable bowel syndrome therapy technology and diagnostic-guided therapy; Helicobacter pylori products, as well as develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.
| EPS | -2.510 |
| Book Value | 1.500 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.083 |
| Profit Margin (%) | -90.31 |
| Operating Margin (%) | -113.47 |
| Return on Assets (ttm) | -49.4 |
| Return on Equity (ttm) | -84.3 |
Tue, 14 Apr 2026
Up to 5 million Canadians have IBS; Biomerica brings inFoods north - Stock Titan
Mon, 13 Apr 2026
Biomerica Reports Third Quarter Fiscal 2026 Financial Results, Highlights Real-World Efficacy of inFoods® IBS and Growth in European Revenue - Quiver Quantitative
Mon, 13 Apr 2026
Biomerica IBS test gets $300 Medicare rate, reports pain relief - Stock Titan
Mon, 13 Apr 2026
Biomerica 10-Q: Revenue $0.99M, EPS $(0.44) for Q3 ended Feb 28, 2026 - TradingView — Track All Markets
Mon, 13 Apr 2026
Biomerica (BMRA) revenue falls 22% as losses persist and going concern risk disclosed - Stock Titan
Thu, 09 Apr 2026
Press Releases about Biomerica, Inc. - Common Stock (Nasdaq:BMRA) - FinancialContent
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |